Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

21.71 -0.39 (-1.76%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atricure Inc

< Previous 1 2 3 4 Next >
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024
ATRC stock results show that AtriCure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
AtriCure Reports First Quarter 2024 Financial Results
From AtriCure, Inc
Via Business Wire
AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
Recap: AtriCure Q4 Earnings
Via Benzinga
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce First Quarter 2024 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
AtriCure's Earnings: A Preview
Via Benzinga
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
From AtriCure, Inc.
Via Business Wire
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Where AtriCure Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
From AtriCure, Inc.
Via Business Wire
AtriCure Appoints Shlomi Nachman to the Board of Directors
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From AtriCure
Via Business Wire
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure Releases 2023 ESG Report
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the Stifel 2023 Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Second Quarter 2023 Financial Results
From AtriCure, Inc.
Via Business Wire
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.